Navigation Links
PDL BioPharma Completes Exchange to Retire $92.0 Million of 2.00% Convertible Notes Due August 2012
Date:11/5/2010

INCLINE VILLAGE, Nev., Nov. 5, 2010 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) announced today that it has completed the exchange of $92.0 million in aggregate principal of the Company's outstanding 2.00% Convertible Senior Notes due February 15, 2012 (the 2012 Notes) in separate, privately negotiated exchange transactions with the note holders.  Pursuant to the exchange transactions, the note holders received $92.0 million in aggregate principal of new 2.875% Convertible Senior Notes due February 15, 2015 (the 2015 Notes).  As part of the transaction, the Company also placed an additional $88.0 million in aggregate principal of the 2015 Notes.  Following the exchange transactions, $136.0 million of the 2012 Notes remain outstanding.  The conversion rate for the 2015 Notes is 140.571 shares of common stock per $1,000 principal amount of the 2015 Notes or $7.11 per share of common stock.  The shares of the Company's common stock issuable upon the conversion of the 2015 Notes have been reserved for issuance by the Company and listed on the Nasdaq Stock Market.

About PDL BioPharma

PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases.  PDL is focused on maximizing the value of its antibody humanization patents and related assets.  The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014.  For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.


'/>"/>
SOURCE PDL BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. PDL BioPharma Announces Exchange to Retire 2.00% Convertible Senior Notes Due February 15, 2012
2. A New BioPharma Intelligence Resource Set to Give Industry Leaders the Edge
3. Reportlinker Adds Downstream Processing in Biopharmaceuticals - Increased Demand for Biologics Drives Improvement in Cost -effective Purification Technologies
4. Biopharma Leaders to Reveal Successful Strategies for China, India at the PharmAsia Summit in San Francisco
5. Helix BioPharma Completes Definitive GLP Toxicology Studies With L-DOS47 and is Making Final Preparations for its Planned Phase I/II Clinical Study IND/CTA Submissions
6. Genesis Biopharma to Present at the Informed Investors Forum Biotech, Healthcare & Pharma Virtual Conference on October 13
7. PDL BioPharma Completes October 1 Special Dividend Payment
8. Genesis Biopharma Announces $700K Private Financing
9. Signal Genetics Announces Partnership with Array BioPharma to Advance a Multiple Myeloma Program Backed by Companion Diagnostics
10. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
11. Helix BioPharma Approved for NYSE Amex Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., today ... , Ph.D., as chief executive officer, as well ... Dr. Schmidt brings to ArmaGen more than 17 years ... and development of biotherapeutics and pharmaceuticals. ... the diverse experience and skillset necessary to lead ...
(Date:1/19/2017)... ... January 19, 2017 , ... FireflySci Inc. is a ... The tremendous growth is accounted to two main factors. The first is ... expanding network of vendors supplying FireflySci products all around the world. , 2016 was ...
(Date:1/19/2017)... -- Acupath Laboratories, Inc., a leading provider of sub-specialized ... Committee that will guide the company,s vision and strategy ... , a 15-year veteran of the anatomic pathology industry, ... Chief Sales Officer .  Prior to joining Acupath ... leadership roles at several leading lab industry organizations including, ...
(Date:1/18/2017)... , Jan. 18, 2017   Boston Biomedical , ... designed to target cancer stemness pathways, will feature data ... napabucasin, at the 2017 ASCO Gastrointestinal Cancers Symposium, held ... . Napabucasin is an orally-administered investigational ... STAT3. i Cancer stem cells (CSCs) possess the ...
Breaking Biology Technology:
(Date:1/12/2017)... 12, 2017 A new report by Allied Market Research, titled, ... biometric technology market is expected to generate revenue of $10.72 billion by 2022, with ... Continue Reading ... Allied Market Research Logo ...      (Logo: http://photos.prnewswire.com/prnh/20140911/647229) In the ...
(Date:1/6/2017)... Calif. , Jan. 5, 2017  Delta ID ... its iris scanning technology for automotive at CESĀ® 2017. ... GNTX ) to demonstrate the use of iris ... identify and authenticate the driver in a car, and ... during the driving experience. Delta ID and ...
(Date:12/22/2016)... NEW YORK , December 22, 2016 ... global provider of secure solutions for the e-Government, Public Safety, HealthCare, ... a subsidiary of SuperCom, has been selected to implement and deploy ... county in Northern California , further expanding its ... ...
Breaking Biology News(10 mins):